Antonio Trujillo, PhD, MPP, is a health economist working to improve access to medicines and the lives of seniors with chronic conditions around the globe.
Findings suggest that Basaglar was not less expensive for patients than Lantus. Empirical evaluation of biosimilar costs prior to automatic substitution is necessary.
